| Blesilda H Olfato, P A | |
|
4544 Shadowleaf Dr Sarasota FL 34233-2278 | |
| (813) 754-7756 | |
| (813) 754-7565 |
| Full Name | Blesilda H Olfato, P A |
|---|---|
| Speciality | Internal Medicine |
| Location | 4544 Shadowleaf Dr, Sarasota, Florida |
| Authorized Official Name and Position | Blesilda H Olfato (PROVIDER) |
| Authorized Official Contact | 9419278213 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Blesilda H Olfato, P A 4544 Shadow Leaf Dr Sarasota FL 34233 Ph: (813) 754-7756 | Blesilda H Olfato, P A 4544 Shadowleaf Dr Sarasota FL 34233-2278 Ph: (813) 754-7756 |
| NPI Number | 1043528474 |
|---|---|
| Provider Enumeration Date | 09/20/2010 |
| Last Update Date | 12/02/2010 |
| Medicare PECOS PAC ID | 8729275532 |
|---|---|
| Medicare Enrollment ID | O20101206001031 |
News Archive
In research at SRI International, scientists evaluating new drug targets against tuberculosis (TB) recently validated the preclinical effectiveness of a target that could rapidly eliminate infections and potentially shorten treatment time. The new drug target is a protein called DNA gyrase B, found in bacteria that cause TB infections.
For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy. That is, the suppression of circulating testosterone - the hormone that fuels prostate-cancer growth - via surgical castration (orchiectomy) or medical castration with testosterone-blocking drugs. While such therapy buys time for patients, it is not a cure, as inevitably the cancer becomes resistant to the androgen deprivation and continues to grow.
End-of-life discussions, considered an essential part of high-quality end-of-life care for patients with life-threatening illnesses, make it easier to provide treatment and care that satisfy the patient's wishes.
A new approach to analyzing prostate gland tissue may help address a major challenge in treating prostate cancer - determining which tumors are unlikely to progress and which could be life threatening and require treatment.
Two of Canada's most eminent health researchers - Dr. Jacques Genest at McGill University and Dr. Michael Hayden at the University of British Columbia - have been awarded the inaugural Margolese National Brain and Heart Disorders Prizes, the most lucrative prizes bestowed by UBC.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043528474 | NPI | - | NPPES |
| 250496100 | Medicaid | FL | |
| 110174189 | Other | FL | MEDICARE RAILROAD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | (* (Not Available)) | Primary |
| Provider Name | Blesilda H Olfato |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1922186485 PECOS PAC ID: 3375668379 Enrollment ID: I20100914001184 |
News Archive
In research at SRI International, scientists evaluating new drug targets against tuberculosis (TB) recently validated the preclinical effectiveness of a target that could rapidly eliminate infections and potentially shorten treatment time. The new drug target is a protein called DNA gyrase B, found in bacteria that cause TB infections.
For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy. That is, the suppression of circulating testosterone - the hormone that fuels prostate-cancer growth - via surgical castration (orchiectomy) or medical castration with testosterone-blocking drugs. While such therapy buys time for patients, it is not a cure, as inevitably the cancer becomes resistant to the androgen deprivation and continues to grow.
End-of-life discussions, considered an essential part of high-quality end-of-life care for patients with life-threatening illnesses, make it easier to provide treatment and care that satisfy the patient's wishes.
A new approach to analyzing prostate gland tissue may help address a major challenge in treating prostate cancer - determining which tumors are unlikely to progress and which could be life threatening and require treatment.
Two of Canada's most eminent health researchers - Dr. Jacques Genest at McGill University and Dr. Michael Hayden at the University of British Columbia - have been awarded the inaugural Margolese National Brain and Heart Disorders Prizes, the most lucrative prizes bestowed by UBC.
› Verified 1 days ago
News Archive
In research at SRI International, scientists evaluating new drug targets against tuberculosis (TB) recently validated the preclinical effectiveness of a target that could rapidly eliminate infections and potentially shorten treatment time. The new drug target is a protein called DNA gyrase B, found in bacteria that cause TB infections.
For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy. That is, the suppression of circulating testosterone - the hormone that fuels prostate-cancer growth - via surgical castration (orchiectomy) or medical castration with testosterone-blocking drugs. While such therapy buys time for patients, it is not a cure, as inevitably the cancer becomes resistant to the androgen deprivation and continues to grow.
End-of-life discussions, considered an essential part of high-quality end-of-life care for patients with life-threatening illnesses, make it easier to provide treatment and care that satisfy the patient's wishes.
A new approach to analyzing prostate gland tissue may help address a major challenge in treating prostate cancer - determining which tumors are unlikely to progress and which could be life threatening and require treatment.
Two of Canada's most eminent health researchers - Dr. Jacques Genest at McGill University and Dr. Michael Hayden at the University of British Columbia - have been awarded the inaugural Margolese National Brain and Heart Disorders Prizes, the most lucrative prizes bestowed by UBC.
› Verified 1 days ago
Cynthia L Collawn Md P A Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1219 S East Ave, Suite 101, Sarasota, FL 34239 Phone: 941-954-4373 | |
Metta Acupuncture & Herbal Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4363 Groveland Ave, Sarasota, FL 34231 Phone: 941-587-6311 | |
Healing Health Care Solutions Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 6157 Anise Dr, Sarasota, FL 34238 Phone: 941-735-9102 | |
Anne Marie Aprn Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2253 Goldenrod St, Sarasota, FL 34239 Phone: 941-266-1922 | |
Arcadia Medical Associates, Pa Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2415 University Pkwy Ste 111, Sarasota, FL 34243 Phone: 941-359-3337 Fax: 941-359-1583 | |
Health Services Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1888 Brother Geenen Way, Sarasota, FL 34236 Phone: 941-556-3215 Fax: 941-955-8214 | |
Healthcare Associates Of Sarasota, P.a. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 7275 Bee Ridge Rd, Sarasota, FL 34241 Phone: 941-927-6607 Fax: 941-921-1834 |